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Introduction
In the mid-1990s, the thiazolides nitazoxanide (NTZ; AliniaTM, 
Romark Laboratories, FL, USA; Table 1) was approved by the FDA 
for treatment of persistent diarrhoea caused by Crypto sporidium 
parvum and Giardia duodenalis in children and adults [1]. Meanwhile, 
a series of NTZ-derivatives had been synthesized and tested for 
activity against intracellular protozoans, bacteria, viruses and tumour 
cells. The respective in vitro, in vivo, and clinical studies have been 
reviewed elsewhere [2]. Susceptibility of G. duodenal is to thiazolides 
is dependent on the presence of a nitro group [3]. Therefore, enzyme 
systems reducing the nitro group to a toxic intermediate or radical have 
been extensively investigated as potential targets in this parasite [4,5].
Soon after its launch, NTZ was investigated with respect to 
potential activities against anaerobic or micro aerophilic bacteria since 
resistance had appeared to the major current drug metronidazole 
[2]. It was found that some metronidazole-resistant strains isolated 
from patients were NTZ susceptible [6]. In clinical studies, NTZ was 
effective against Clostridium difficile colitis [7,8]. Moreover, NTZ 
derivatives have been identified that may have greater efficacy than 
NTZ against C. difficile and the microaerophilic Campylobacter jejuni 
and Helicobacter pylori [9,10]. In the anaerobic or micro aerophilic 
bacteria, reduction of the nitro group is regarded as the main mode 
of action [11,12]. Interestingly, in vitro studies indicate that NTZ and 
analogues may be active against aerobic bacteria such as Escherichia 
coli [13], Mycobacterium tuberculosis [14-16], and Staphylococcus sp. 
[10,17]. This is of particular interest since these pathogens often exhibit 
multidrug resistance against traditional antibiotics. 
NTZ may also interact with membranes. In M. tuberculosis, NTZ 
disrupts the membrane potential and pH homeostasis in a similar 
way as the salicylanilide niclosamide [15]. In E. coli, the molecular 
mechanisms of action are unknown, and it is even unclear whether the 
inhibition of bio film production by the strains described in [13] can be 
generalized to an inhibition of other strains. In our experiments, E. coli BL 
21 was not susceptible to NTZ, but became susceptible under semi-aerobic 
conditions only after expression of a G. duodenal is nitro reductase 
[5,18]. 
When investigating antibacterial effects of thiazolides and other 
compounds against E. coli, one must be aware that efflux pumps 
constitute a barrier that these compounds have to overcome. tolC is a 
channel-forming protein in the outer membrane that forms a complex 
with nine known inner-membrane efflux pumps and their cognate 
periplasmic membrane fusion proteins [19]. The tripartite complex 
forms a conduit for efflux of endogenous compounds and xenobiotics 
[20,21]. Deletion of tolC leads to increased susceptibility to a great 
variety of antibiotics, un couplers, detergents and other substances 
showing that it is the most important outer membrane protein involved 
in multidrug resistance [22]. Besides Acr B, eight other efflux pumps 
have been shown to be dependent on tolC for their efflux activities [23]. 
In the absence of tolC, none of these pumps are functional. E. coli tolC 
mutants have been used as model systems to investigate the mode of 
action of antibiotics such as rifamycin [24].
In order to investigate in more detail the antibacterial potential of 
thiazolides, we tested the susceptibility of E. coli strains lacking tolC 
to thiazolides with nitro or bromo group substitutions (Table 1). In 
addition, we have used strains carrying spy:: lacZ transcriptional 
fusions to test whether the thiazolides generate stress in the bacterial 
envelope. The expression of spy (encoding a periplasmic chaperone of 
proteins) is a good reporter of activation of the Bae and Cpx stress-
response systems which respond to misfolded envelope proteins [25].
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Materials and Methods
E. coli strains
The E. coli strains used in this study are listed in (Table 2).
Chemicals
If not otherwise stated, all biochemical reagents were from 
Sigma Life Science (St Louis, MO, USA). NTZ was synthesized at 
the Department of Chemistry and Biochemistry, University of Berne 
(kindly provided by Ch. Leumann). The other thiazolides were 
synthesized at the Department of Chemistry, University of Liverpool, 
which is gratefully acknowledged. The thiazolides, carbonyl cyanide-
m-chlorophenyl hydrazone (CCCP), and nalidixic acid were kept as 
100 mm stock solutions in DMSO at -20°C. 
Determination of drug susceptibility
Drug susceptibilities of the E. coli strains listed in (Table 2) were 
tested by a conventional disc diffusion agar procedure [5]. For this 
purpose, bacteria were grown to late logarithmic phase (A600 nm=1) 
in Luria-Bertani-medium (LB). Those strains harbouring a plasmid 
with an ampicillin resistance marker were grown in the same medium 
containing 100 µg mL-1 ampicillin. Then, 0.3 mL of bacterial suspensions 
was streaked on LB agar plates (9 cm diameter petri dishes containing 
20 mL agar medium ± 100 µg mL-1 ampicillin). Whitman filter discs (5 
mm diameter) were soaked with 7 µL of compound solutions or solvent 
controls as indicated. The discs were air-dried for 5 min, and placed 
on the plates. The plates were incubated at 37°C for 24 h in a humid 
chamber. Then, growth inhibition zone diameters were measured and 
the surface of the inhibition zones around the disc was indicated (in 
mm2) after subtraction of the surface of the disks (19.6 mm2).
Beta-galactosidase assay in E coli reporter strains
Overnight cultures of E. coli strains M5402 (WT) and M5403 (tolC) 
carrying spy::lacZ transcriptional fusions in LB medium were diluted 
10-fold in LB and aerated for 1 h at 37oC to an A600 of 0.5. The cells (0.75 
ml) were then diluted with equal volumes of pre warmed LB containing 
compounds or solvent controls as indicated and aerated for 120 min at 
37oC. The cells were then assayed for beta-galactosidase specific activity 
(expressed in Miller units) as previously described [23].
Statistical methods
Statistical analysis of the results was performed with suitable tools 
from the open source software package R [26]. Differences exhibiting p 
values of <0.01 were considered significant. 
Results
Strains defective in the tolC-dependent efflux system and 
corresponding wild type strains (Table 2) were tested by disc diffusion 
assays with four thiazolides, two with a nitro group (including NTZ) 
and two with a bromo group. Moreover, nalidixic acid has been 
included as a positive control for a tolC-dependent antibiotic [22]. 
In a previous study, we had found that NTZ was inhibitory for E. 
coli growth but only when a) the Giardianitro reductase GINR1 was 
expressed in the cells and b) when they were grown in semi-aerobic but 
not aerobic conditions [5] suggesting that bromo-thiazolides would 
not be effective. In fact, all of the tolC mutants were susceptible to 
Figure1 : E. coli efflux pump mutants are susceptible to thiazolides. 
Susceptibility of E. Coli efflux pump mutants and their corresponding wildtypes 
(listed in Table 2) to nalidixic acid (A) and to thiazolides (listed in Table 1) with 
a nitro group (B) or a bromo group (C). Susceptibilities were determined by 
disc diffusion assays as described in Materials & Methods. Discs were soaked 
with stock solutions yielding initial amounts of 700 n moles of thiazolides or 
7 nmoles of nalidixic acid in the disks or with equal amounts of DMSO as a 
solvent control. Mean values ± SE of the surfaces of the inhibition zones are 
given for 3 replicates. Values marked by asterisks are significantly different 
from the control (paired t-test, two-sided, *, p<0.01).
Compound X R2
NTZ
(Nitro 1)
NO2 H
Nitro2 NO2 CH3
Bromo1 Br H
Bromo2 Br CH3
Table1: Overview of thiazolide compounds mentioned in this article. R1 was 
OCOCH3, Y, R3 and R4 wereH for all compounds.
Strain Relevant 
genotype
Description Reference
M5402 Spy : lacZ Wild type of M5403 [23]
M5403 /p TolC tolC /pTrc99AtolC+ Complemented tolC-mutant [23]
N7829 (GC4468) Wild type of M5652 [23]
M5403 tolC spy::lacZ Defective for tolC-mediated efflux [23]
M5403/pTrc99A pTrc99AAmpr Defective for tolC-mediated efflux [23]
M5403/pTolC-
turn1 mutant 
Defective for tolC-mediated efflux [29]
M5652 tolC Defective for tolC-mediated efflux this study
Table 2: Bacterial strains used in this study.
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thiazolidesas well as to nalidixic acid, and the thiazolides with a bromo 
group gave even larger inhibitory zones than when a nitro group was 
present. The presence of a methyl group did not alter this picture 
(Figure 1). There was no detectable inhibition zone with DMSO as a 
solvent control.
To test whether thiazolides engender a stress response in E. coli, we 
assayed the M5402 (WT) and M5403 (tolC) strains for the expression 
of a spy: lacZ transcriptional fusion, an indicator of cell envelope stress. 
As previously shown, nalidixic acid induced spy expression in tolC, but 
not in the wild type [23]. All four thiazolides induced spy expression in 
the tolC mutant but not in the wild type indicating that nitro-reduction 
is not necessary for this effect (Figure 2). 
These findings prompted us to investigate whether E. coli wild 
type strains may be inhibited by thiazolides in the presence of a tolC 
inhibitor. To inhibit tolC, we chose CCCP in amounts that inhibit tolC 
efflux, but not growth [27,28], in our case 14 nmol. Previous tests had 
shown that initial amounts of 28 n mol CCCP and more gave clear 
inhibition zones around the disk (data not shown). As shown in Figure 
3, NTZ and the bromothiazolide caused distinct inhibition zones 
with the strain N7829 reaching plateaus at 175 nmoles of compounds 
initially applied on the disk. Similar results were obtained with wild 
type M5602 (data not shown).
Discussion
Our results show that tolC mutants of E. coli are susceptible to both 
nitro- and bromo-thiazolides. The tolC protein has to be functional 
since a mutation in turn 1 of the protein [29] is sufficient to induce 
thiazolide susceptibility. This is strong evidence that resistance to these 
drugs in E. coli is promoted by TolC-dependent efflux reducing the 
active concentration of the drug. Furthermore, the sensitivity seen in 
the tolC mutants is unlikely to be due to a mechanism involving partial 
reduction of the nitro group. 
Another interesting clue to the mechanism of action of the 
thiazolides in E. coli is our finding that they increase expression of a 
spy::lacZ transcriptional fusion. This suggests that they increase mis 
folding of envelope proteins. Perhaps this is related to the disruption 
of the membrane potential and pH homeostasis brought about by NTZ 
in M. tuberculosis [15].
Taken together, thiazolides clearly exhibit antibacterial activities 
also against gram negative, aerobically growing bacteria such as E. 
coli. In wild type E. coli, this effect is, however, blocked by the presence 
of the tolC dependent efflux system. Inhibition of this efflux system, 
e. g. by sub lethal concentrations of CCCP, renders E. coli wild types 
susceptible to thiazolides. Thus, applied together with a more specific 
efflux pump inhibitor [30], thiazolides may provide an alternative to 
present chemotherapies, even in difficult cases such as S. aureus [31].
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